The genetic drug developer is targeting up to $86m in an IPO that would enable Alexandria Venture Investments to score an exit.

Stoke Therapeutics, a US-based genetic medicine developer backed by life sciences real estate investment trust Alexandria Real Estate Equities, has filed for an initial public offering. The company plans to float on the Nasdaq Global Select Market and has set a placeholder figure of $86m as a target. Founded in 2014, Stoke is developing drugs…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.